Table 2. Clinical features of 18... | American Society of Hematology

Table 2.

Clinical features of 18 patients with late hepatitis B virus-related hepatitis

	Recipient HBV status before HSCT					Donor HBV status before HSCT					Preemptive nucleoside analog	Time after HSCT of late HBV reactivation, mo	Treated with lamivudine after reactivation	Recipient HBV status at the end of follow-up					Fulminant hepatic failure
Patient no.	HBsAg	HBeAg	Anti-HBe	HBsAg	Anti-HBs	Anti-HBc				HBsAg	Preemptive nucleoside analog	Time after HSCT of late HBV reactivation, mo	Treated with lamivudine after reactivation	HBeAg	Anti-HBe		Outcome		Fulminant hepatic failure
1	-	-	-	-	-	+	N	18.5	Y	+	-	+	N	Chronic HBV
2	-	-	-	-	-	+	N	24.6	Y	+	-	+	N	Chronic HBV
3	+	+	-	+	-	+	N	12.4	N	+	-	+	N	Died
4	+	-	+	+	+	+	FAM	12.4	Y	+	-	+	Y	Died
5	+	-	+	-	-	+	LAM	15.7	Y	+	-	+	N	Alive
6	+	-	+	+	-	+	LAM	16.4	Y	+	-	+	Y	Alive
7	+	-	+	+	-	-	LAM	18.8	Y	+	-	+	N	Died
8	+	+	-	-	+	-	N	19.3	N	+	-	+	N	Alive
9	+	-	+	-	-	+	LAM	24.5	Y	+	-	+	Y	Alive
10	+	+	-	-	-	+	LAM	29.3	N	+	-	+	Y	Died
11	+	-	+	+	-	-	LAM	38.2	Y	+	-	+	N	Alive
12	+	+	-	+	+	-	FAM	44.2	Y	+	+	-	N	Alive
13	+	+	-	-	+	+	FAM	60.6	Y	+	+	-	N	Alive
14	+	-	+	-	-	+	N	73.3	Y	+	-	+	N	Died
15	+	-	+	+	-	+	FAM	78.1	Y	+	-	+	N	Alive
16	+	+	-	-	-	-	N	109.9	Y	+	-	+	N	Died
17	+	-	+	-	-	+	N	111.7	Y	+	-	+	N	Alive
18	+	+	-	-	-	+	N	119.8	Y	+	-	+	N	Alive

	Recipient HBV status before HSCT					Donor HBV status before HSCT					Preemptive nucleoside analog	Time after HSCT of late HBV reactivation, mo	Treated with lamivudine after reactivation	Recipient HBV status at the end of follow-up					Fulminant hepatic failure
Patient no.	HBsAg	HBeAg	Anti-HBe	HBsAg	Anti-HBs	Anti-HBc				HBsAg	Preemptive nucleoside analog	Time after HSCT of late HBV reactivation, mo	Treated with lamivudine after reactivation	HBeAg	Anti-HBe		Outcome		Fulminant hepatic failure
1	-	-	-	-	-	+	N	18.5	Y	+	-	+	N	Chronic HBV
2	-	-	-	-	-	+	N	24.6	Y	+	-	+	N	Chronic HBV
3	+	+	-	+	-	+	N	12.4	N	+	-	+	N	Died
4	+	-	+	+	+	+	FAM	12.4	Y	+	-	+	Y	Died
5	+	-	+	-	-	+	LAM	15.7	Y	+	-	+	N	Alive
6	+	-	+	+	-	+	LAM	16.4	Y	+	-	+	Y	Alive
7	+	-	+	+	-	-	LAM	18.8	Y	+	-	+	N	Died
8	+	+	-	-	+	-	N	19.3	N	+	-	+	N	Alive
9	+	-	+	-	-	+	LAM	24.5	Y	+	-	+	Y	Alive
10	+	+	-	-	-	+	LAM	29.3	N	+	-	+	Y	Died
11	+	-	+	+	-	-	LAM	38.2	Y	+	-	+	N	Alive
12	+	+	-	+	+	-	FAM	44.2	Y	+	+	-	N	Alive
13	+	+	-	-	+	+	FAM	60.6	Y	+	+	-	N	Alive
14	+	-	+	-	-	+	N	73.3	Y	+	-	+	N	Died
15	+	-	+	+	-	+	FAM	78.1	Y	+	-	+	N	Alive
16	+	+	-	-	-	-	N	109.9	Y	+	-	+	N	Died
17	+	-	+	-	-	+	N	111.7	Y	+	-	+	N	Alive
18	+	+	-	-	-	+	N	119.8	Y	+	-	+	N	Alive

LAM indicates lamivudinc; FAM, famciclovir; Y, yes; N, no; +, positive; and -, negative.